U.S. Pharmas Rank 2nd To Tech Sector In Cash, But Spend It Differently, Moody’s Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In an analysis of non-financial sector U.S.-based companies, Moody’s ranks pharma a remote second to the tech sector in terms of aggregate cash held as of mid-2013. While capital expenditures lead the aggregate group’s spending priorities, dividends and share buybacks top pharma’s list. Companies keep most of their cash overseas, a continuing trend.
You may also be interested in...
Pharmas Among Biggest Cash Hoarders, Moody’s Finds
A Moody’s report lists seven pharmas among the 50 non-financial companies sitting on the largest piles of cash. These very big war chests hold the preferred currency, particularly for ex-U.S.pharma deal-making.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Ketamine May Shake Up The Treatment Of Major Depression
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.